公开(公告)号：US11406625B2

公开(公告)日：2022-08-09

申请号：US16789564

申请日：2020-02-13

Applicant: PRILENIA NEUROTHERAPEUTICS LTD.

Inventor： Michal Geva ,  Ralph Laufer ,  Michael Hayden ,  Neta Zach

IPC: A61K31/44 ,  A61P25/14 ,  A61K9/00 ,  A61K31/185 ,  A61K31/222 ,  A61K31/4152 ,  A61K31/426 ,  A61K31/4748 ,  A61K31/49

Abstract: Provided herein is a method for treating a human subject afflicted with ALS by administering to the subject a therapeutically effective amount of pridopidine as monotherapy or together with riluzole, edaravone, combination of dextromethorphan/quinidine, sodium phenylbutyrate (PB), tauroursodeoxycholic acid or combination of sodium phenylbutyrate (PB)/tauroursodeoxycholic acid (i.e. AMX0035) as combination or add-on therapy.

公开(公告)号：US20210275512A1

公开(公告)日：2021-09-09

申请号：US17315667

申请日：2021-05-10

Applicant: PRILENIA NEUROTHERAPEUTICS LTD.

Inventor： Michal GEVA ,  Aric Orbach ,  Michael Hayden

IPC: A61K31/451 ,  A61P25/14 ,  A61K45/06 ,  A61P25/16 ,  A61K9/00

Abstract: The invention provides a method of treating a subject afflicted with a drug-induced movement disorder including levodopa-induced dyskinesia comprising periodically administering to the subject in need thereof an amount of pridopidine or pharmaceutically acceptable salt thereof effective to treat the subject. The invention further provides a method of treating a subject at risk of developing a drug-induced movement disorder, including levodopa-induced dyskinesia

公开(公告)号：US11207310B2

公开(公告)日：2021-12-28

申请号：US15685993

申请日：2017-08-24

Applicant: PRILENIA NEUROTHERAPEUTICS LTD.

Inventor： Michael Hayden ,  Spyridon Papapetropoulos ,  Juha-Matti Savola ,  Eli Eyal ,  Beth Borowsky ,  Igor Grachev

IPC: A61K31/451 ,  A61K9/00

Abstract: This invention provides a method of maintaining functional capacity, improving functional capacity, or lessening the decline of functional capacity in a human patient comprising periodically orally administering to the patient a pharmaceutical composition comprising pridopidine such that a dose of 90-225 mg of pridopidine is administered to the patient per day, so as to thereby maintain functional capacity, improve functional capacity, or lessen the decline of functional capacity in the human patient.

公开(公告)号：US11000519B2

公开(公告)日：2021-05-11

申请号：US16436947

申请日：2019-06-11

Applicant: PRILENIA NEUROTHERAPEUTICS LTD.

Inventor： Michal Geva ,  Aric Orbach ,  Michael Hayden

IPC: A61K31/445 ,  A61K31/451 ,  A61P25/14 ,  A61K45/06 ,  A61P25/16 ,  A61K9/00 ,  A61K31/198

Abstract: The invention provides a method of treating a subject afflicted with a drug-induced movement disorder including levodopa-induced dyskinesia comprising periodically administering to the subject in need thereof an amount of pridopidine effective to treat the subject. The invention further provides a method of treating a subject at risk of developing a drug-induced movement disorder, including levodopa-induced dyskinesia. The invention also provides pharmaceutical compositions suitable for carrying out these methods and packages containing such pharmaceutical compositions.

公开(公告)号：US20200093813A1

公开(公告)日：2020-03-26

申请号：US16591875

申请日：2019-10-03

Applicant: PRILENIA NEUROTHERAPEUTICS LTD. ,  THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM

Inventor： Michal Geva ,  Ilya Bezprozvanny ,  Merav Bassan ,  Michael Hayden

IPC: A61K31/451 ,  A61P25/28 ,  A61P25/08

Abstract: This invention provides a method of improving cognitive function in a subject comprising periodically administering to the subject an amount of pridopidine or a pharmaceutically acceptable salt thereof effective to improve a cognitive function in the subject.The invention also provides a method of treating a subject afflicted with Alzheimer's disease, comprising periodically administering to the subject a pharmaceutical composition comprising an amount of pridopidine or a pharmaceutically acceptable salt thereof effective to treat the subject.

公开(公告)号：US12036213B2

公开(公告)日：2024-07-16

申请号：US17315667

申请日：2021-05-10

Applicant: PRILENIA NEUROTHERAPEUTICS LTD.

Inventor： Michal Geva ,  Aric Orbach ,  Michael Hayden

IPC: A61K31/451 ,  A61K9/00 ,  A61K45/06 ,  A61P25/14 ,  A61P25/16 ,  A61K31/198

CPC classification number: A61K31/451 ,  A61K9/0053 ,  A61K45/06 ,  A61P25/14 ,  A61P25/16 ,  A61K31/198

Abstract: The invention provides a method of treating a subject afflicted with a drug-induced movement disorder including levodopa-induced dyskinesia comprising periodically administering to the subject in need thereof an amount of pridopidine or pharmaceutically acceptable salt thereof effective to treat the subject. The invention further provides a method of treating a subject at risk of developing a drug-induced movement disorder, including levodopa-induced dyskinesia.

公开(公告)号：US11234973B2

公开(公告)日：2022-02-01

申请号：US16514167

申请日：2019-07-17

Applicant: PRILENIA NEUROTHERAPEUTICS LTD. ,  NATIONAL UNIVERSITY OF SINGAPORE ,  AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH

Inventor： Michael Hayden ,  Mahmoud Abdulhossein Pouladi

IPC: A61K31/451 ,  A61K9/00 ,  A61P43/00 ,  A61K45/06

Abstract: The invention provides a method of treating a subject afflicted with fragile X syndrome (FXS) or a FXS related disorder, comprising periodically administering to the subject a pharmaceutical composition comprising an amount of pridopidine effective to treat the subject.

公开(公告)号：US10603311B2

公开(公告)日：2020-03-31

申请号：US15052368

申请日：2016-02-24

Applicant: PRILENIA NEUROTHERAPEUTICS LTD.

Inventor： Michal Geva ,  Ilya Bezprozvanny ,  Merav Bassan ,  Michael Hayden

IPC: A61K31/451 ,  C07D211/24 ,  C07D211/52 ,  C07D211/42

Abstract: This invention provides a method of improving cognitive function in a subject comprising periodically administering to the subject an amount of pridopidine or a pharmaceutically acceptable salt thereof effective to improve a cognitive function in the subject.The invention also provides a method of treating a subject afflicted with Alzheimer's disease, comprising periodically administering to the subject a pharmaceutical composition comprising an amount of pridopidine or a pharmaceutically acceptable salt thereof effective to treat the subject.

公开(公告)号：US12102627B2

公开(公告)日：2024-10-01

申请号：US16952123

申请日：2020-11-19

Applicant: PRILENIA NEUROTHERAPEUTICS LTD.

Inventor： Michal Geva ,  Ralph Laufer ,  Michael Hayden

IPC: A61K31/451 ,  A61K9/00 ,  A61P25/14

CPC classification number: A61K31/451 ,  A61K9/0019 ,  A61K9/0053 ,  A61P25/14

Abstract: The subject invention provides a method for treating a subject afflicted with Rett syndrome comprising administering to the subject an effective amount of pridopidine so as to thereby treat the subject.

公开(公告)号：US11471449B2

公开(公告)日：2022-10-18

申请号：US16591875

申请日：2019-10-03

Applicant: PRILENIA NEUROTHERAPEUTICS LTD. ,  THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM

Inventor： Michal Geva ,  Ilya Bezprozvanny ,  Merav Bassan ,  Michael Hayden

IPC: A61P25/08 ,  A61K31/451 ,  A61P25/28 ,  A61K45/06

Abstract: This invention provides a method of improving cognitive function in a subject comprising periodically administering to the subject an amount of pridopidine or a pharmaceutically acceptable salt thereof effective to improve a cognitive function in the subject.
The invention also provides a method of treating a subject afflicted with Alzheimer's disease, comprising periodically administering to the subject a pharmaceutical composition comprising an amount of pridopidine or a pharmaceutically acceptable salt thereof effective to treat the subject.